Vera Therapeutics, Inc.
atacicept
IgA Nephropathy (IgAN)
Resolved
45days ago
FDA decision · Jul 7, 2026
What's at stake
The FDA's approval decision on atacicept for IgA Nephropathy (IgAN) is due Jul 7, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 2mo ago
“U.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for atacicept with Prescription Drug User Fee Act (PDUFA) date of July 7, 2026”